Log odds of negative lymph nodes/T stage as a novel predictor of post-resection outcome in non-small cell lung cancer patients

阴性淋巴结/T分期的对数比值作为非小细胞肺癌患者术后预后的新型预测指标

阅读:1

Abstract

BACKGROUND: Surgery with systematic lymph node (LN) dissection remains the primary treatment for early-stage and locally advanced operable non-small-cell lung cancer (NSCLC). However, the effect of the log odds of negative lymph nodes/T stage (LONT) in NSCLC remains unclear. This study aims to evaluate the correlation between LONT and prognosis of stage I-III NSCLC patients who underwent resection. METHODS: Clinical data from patients who underwent NSCLC resection were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The log odds of negative LONT, defined as log(NLNs + 1)/T stage, was calculated for each patient. The nonlinear relationship between LONT and overall survival (OS) and lung cancer-specific survival (LCSS) was evaluated using the cubic spline smoothing technique and Cox regression. The optimal LONT cut-off point was determined using X-tile plots, and propensity score matching (PSM) was performed to minimize inter-group differences. RESULTS: LONT demonstrated a nonlinear positive relationship with both OS and LCSS. Based on X-tile plot-determined cut-off point of 0.60, participants were categorized into low (< 0.60) and high (≥ 0.60) LONT subgroups. Both before and after PSM, the high LONT group exhibited significantly better OS and LCSS compared to the low LONT group (both P < 0.001). Similar survival differences were observed in subgroup analyses based on lymph node status and TNM stage. LONT was an independent predictor of OS (HR: 0.78, 95% CI: 0.74-0.81, P < 0.001) and LCSS (HR: 0.75, 95% CI: 0.71-0.78, P < 0.001). CONCLUSIONS: LONT is a novel robust prognostic factor that could complement TNM staging system. A higher LONT is associated with better survival in stage I-III NSCLC patients who received resection.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。